epinephrine
Pre-clinical- Indications
- Anaphylaxis
Company intelligence / Profile preview
Windgap Medical develops innovative drug delivery devices—primarily autoinjectors—for complex injectables such as lyophilized/powdered drugs requiring rapid reconstitution, high-viscosity medications, and large-volume injections. Their lead product targets the self-administration of epinephrine for anaphylaxis. The company’s platforms are designed to simplify administration, improve portability, and accelerate time-to-injection compared to traditional methods. They have demonstrated significant reductions in drug reconstitution time in feasibility studies.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Windgap Medical.